Article

Novartis to market antibody fragment

Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension
June 30th 2025

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Nanoscope Therapeutics forms Vision Advisory Committee
June 30th 2025

Nanoscope Therapeutics forms Vision Advisory Committee

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME
June 28th 2025

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME

PYC to finalize registrational study for RP11 after positive FDA feedback
June 28th 2025

PYC to finalize registrational study for RP11 after positive FDA feedback

© 2025 MJH Life Sciences

All rights reserved.